Protalix BioTherapeutics, Inc. Operating Income Loss

• Protalix BioTherapeutics, Inc. showed a decrease of -240.4% in Operating Income Loss from 2024 to 2025.
• This data is from Protalix BioTherapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 18, 2026.
• XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 17 years of available data (2009 to 2025), Protalix BioTherapeutics, Inc.'s Operating Income Loss has grown by 82.8%.
• Historical annual values: Fiscal year 2025: -$5.50 million | Fiscal year 2024: $3.92 million | Fiscal year 2023: $10.46 million | Fiscal year 2022: -$13.01 million | Fiscal year 2021: -$20.46 million | Fiscal year 2020: $2.71 million | Fiscal year 2019: -$10.72 million | Fiscal year 2018: -$19.31 million | Fiscal year 2017: -$34.52 million | Fiscal year 2016: -$33.16 million | Fiscal year 2015: -$23.67 million | Fiscal year 2014: -$28.56 million | Fiscal year 2013: -$34.06 million | Fiscal year 2012: -$12.17 million | Fiscal year 2011: -$36.53 million | Fiscal year 2010: -$29.97 million | Fiscal year 2009: -$31.97 million.
• Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: June 22, 2026